|

Pelabresib Clinical Trials

3 actively recruiting trials across 1 location

▲ +1 trial since June 2026

Also known as: CPI-0610, DAK539 (formerly CPI-0610)

Pipeline

Phase 1: 2Phase 3: 1

Top Sponsors

  • Novartis Pharmaceuticals3

Indications

  • Cancer3
  • Advanced Malignancies2
  • Advanced Malignancies and Hepatic Impairment1
  • Hematologic Malignancy1
  • Solid Tumor1

Other2 trials

A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies
Phase 1
Pharmacokinetics and Safety Study of Pelabresib in Patients With Advanced Malignancies and Hepatic Impairment
Phase 1

Los Angeles, California1 trial

An Extension Study for Patients Previously Enrolled in Studies With Pelabresib

University of California LA

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.